Mga Batayang Estadistika
| CIK | 1595893 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Turning Point Therapeutics Inc
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-38871 TURNING POINT THERAPEUTICS, INC. (Exact name of registrant as spe |
|
| August 17, 2022 |
As filed with the Securities and Exchange Commission on August 17, 2022 As filed with the Securities and Exchange Commission on August 17, 2022 Registration No. |
|
| August 17, 2022 |
Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TURNING POINT THERAPEUTICS, INC. ARTICLE ONE The name of the corporation is Turning Point Therapeutics, Inc. (hereinafter called the ?Corporation?). ARTICLE TWO The address of the Corporation?s registered office in the State of Delaware is 251 Little Falls Drive, Wilmington, New Castle, Delaware 19808. The name of its register |
|
| August 17, 2022 |
SECOND AMENDED AND RESTATED TURNING POINT THERAPEUTICS, INC. A Delaware Corporation ARTICLE I Exhibit 3.2 SECOND AMENDED AND RESTATED BYLAWS OF TURNING POINT THERAPEUTICS, INC. A Delaware Corporation ARTICLE I OFFICES Section 1.1 Registered Office. The registered office of the corporation in the State of Delaware shall be located at 251 Little Falls Drive, Wilmington, Delaware 19808, in the County of New Castle. The name of the corporation?s registered agent at such address shall be Corpor |
|
| August 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2022 Turning Point Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) (C |
|
| August 17, 2022 |
As filed with the Securities and Exchange Commission on August 17, 2022 S-8 POS 1 brhc10040737s8pos.htm S-8 POS As filed with the Securities and Exchange Commission on August 17, 2022 Registration No. 333-231372 Registration No. 333-237250 Registration No. 333-253711 Registration No. 333-263079 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: FORM S-8 REGISTRATION STATEMENT NO. 333-231372 FORM S-8 REGISTRATION |
|
| August 17, 2022 |
As filed with the Securities and Exchange Commission on August 17, 2022 As filed with the Securities and Exchange Commission on August 17, 2022 Registration No. |
|
| August 17, 2022 |
As filed with the Securities and Exchange Commission on August 17, 2022 POS AM 1 brhc10040741posam.htm POS AM As filed with the Securities and Exchange Commission on August 17, 2022 Registration No. 333-238300 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: FORM S-3 REGISTRATION STATEMENT NO. 333-238300 UNDER THE SECURITIES ACT OF 1933 Turning Point Therapeutics, Inc. (Exact name of registrant as specified in |
|
| August 17, 2022 |
As filed with the Securities and Exchange Commission on August 17, 2022 As filed with the Securities and Exchange Commission on August 17, 2022 Registration No. |
|
| August 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 4) TURNING POINT THERAPEUTICS, INC. (Name of Subject Company (Issuer)) RHUMBA MERGER SUB INC. (Offeror) A Wholly Owned Subsidiary of BRISTOL-MYERS SQUIBB COMPANY (Parent of Offeror) (Names of Filing Perso |
|
| August 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 4) TURNING POINT THERAPEUTICS, INC. (Name of Subject Company) Turning Point Therapeutics, Inc. (Name of Person Filing Statement) Common Stock, $0.0001 par value per share (Title of Class of Securiti |
|
| August 16, 2022 |
Exhibit 99.1 (a)(5)(ix) Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Therapeutics Tuesday, August 16, 2022 (NEW YORK & SAN DIEGO)- Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) (?Turning Point?) today announced |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) TURNING POINT THERAPEUTICS, INC. (Name of Subject Company) Turning Point Therapeutics, Inc. (Name of Person Filing Statement) Common Stock, $0.0001 par value per share (Title of Class of Securiti |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) TURNING POINT THERAPEUTICS, INC. (Name of Subject Company (Issuer)) RHUMBA MERGER SUB INC. (Offeror) A Wholly Owned Subsidiary of BRISTOL-MYERS SQUIBB COMPANY (Parent of Offeror) (Names of Filing Perso |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2022 Turning Point Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) (C |
|
| August 8, 2022 |
Exhibit 10.3 Amendment No. 1 to Executive Employment Agreement This Amendment No. 1 to Executive Employment Agreement (?Amendment?) between Turning Point Therapeutics, Inc. with its principal place of business at 10628 Science Center Drive, Suite 200, San Diego, CA 92121 (?Turning Point?) and Mohammad Hirmand, M.D. (?Executive?) is entered into between Turning Point and Executive effective as of M |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38871 Turning Point Therapeutics, Inc. |
|
| August 8, 2022 |
License Agreement, dated May 4, 2022, by and between the Registrant and LaNova Medicines Limited. Exhibit 10.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Confidential Execution copy LICENSE AGREEMENT This License Agreement (this ?Agreement?) is made as of May 4, 2022 (the ?Effective Date?), by and betw |
|
| August 8, 2022 |
Exhibit 99.1 Contact: Adam D. Levy, Ph.D., M.B.A. [email protected] 858-867-6366 TURNING POINT THERAPEUTICS REPORTS SECOND-QUARTER 2022 FINANCIAL RESULTS, PROVIDES OPERATIONAL UPDATES ? Positive feedback from pre-new drug application (NDA) meeting with U.S. Food and Drug Administration (FDA) focused on TRIDENT-1 registrational study of repotrectinib ? Initiated the Phase 1b/2 SHIELD-2 combinat |
|
| August 8, 2022 |
Exhibit 10.2 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. STRATEGIC COLLABORATION AGREEMENT This Strategic Collaboration Agreement (?Agreement?), effective as of the 23rd day of June, 2022 (?Effective Date?) |
|
| July 19, 2022 |
Bristol Myers Squibb Announces Extension of Turning Point Tender Offer Exhibit (a)(5)(viii) Bristol Myers Squibb Announces Extension of Turning Point Tender Offer (NEW YORK, July 19, 2022) ? Bristol Myers Squibb (NYSE:BMY) today has announced that Rhumba Merger Sub Inc. |
|
| July 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) TURNING POINT THERAPEUTICS, INC. (Name of Subject Company (Issuer)) RHUMBA MERGER SUB INC. (Offeror) A Wholly Owned Subsidiary of BRISTOL-MYERS SQUIBB COMPANY (Parent of Offeror) (Names of Filing Perso |
|
| July 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) TURNING POINT THERAPEUTICS, INC. (Name of Subject Company) Turning Point Therapeutics, Inc. (Name of Person Filing Statement) Common Stock, $0.0001 par value per share (Title of Class of Securiti |
|
| July 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14a(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) TURNING POINT THERAPEUTICS, INC. (Name of Subject Company (Issuer)) RHUMBA MERGER SUB INC. (Offeror) A Wholly Owned Subsidiary of BRISTOL-MYERS SQUIBB COMPANY (Parent of Offeror) (Names of Filing Pers |
|
| July 1, 2022 |
SC 14D9/A 1 brhc10039322sc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) TURNING POINT THERAPEUTICS, INC. (Name of Subject Company) Turning Point Therapeutics, Inc. (Name of Person Filing Statement) Common Stock, $0.0001 p |
|
| June 24, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2022 Turning Point Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) (Com |
|
| June 21, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2022 Turning Point Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) (Com |
|
| June 17, 2022 |
Exhibit (a)(1)(v) Offer to Purchase for Cash All Outstanding Shares of Common Stock ? of ? Turning Point Therapeutics, Inc. |
|
| June 17, 2022 |
Exhibit (a)(1)(iv) Offer to Purchase for Cash All Outstanding Shares of Common Stock ? of ? Turning Point Therapeutics, Inc. |
|
| June 17, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 TURNING POINT THERAPEUTICS, INC. (Name of Subject Company) TURNING POINT THERAPEUTICS, INC. (Name of Person Filing Statement) Common Stock, $0.0001 par value per share (Title of Class of Securiti |
|
| June 17, 2022 |
SC TO-T 1 ny20004554x1sctot.htm SC TOT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 TURNING POINT THERAPEUTICS, INC. (Name of Subject Company (Issuer)) RHUMBA MERGER SUB INC. (Offeror) A Wholly Owned Subsidiary of BRISTOL-MYERS SQUIBB COMPANY (Parent of Offeror) ( |
|
| June 17, 2022 |
Exhibit 107 Calculation of Filing Fee Tables ? Schedule TO-T ? (Rule 14d-100) ? TURNING POINT THERAPEUTICS, INC. |
|
| June 17, 2022 |
Exhibit (a)(1)(iii) NOTICE OF GUARANTEED DELIVERY to Tender Shares of Common Stock ? of TURNING POINT THERAPEUTICS, INC. |
|
| June 17, 2022 |
Exhibit (a)(1)(ii) LETTER OF TRANSMITTAL to Tender Shares of Common Stock ? of ? TURNING POINT THERAPEUTICS, INC. |
|
| June 17, 2022 |
Exhibit (a)(1)(vi) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| June 17, 2022 |
TABLE OF CONTENTS Exhibit (a)(1)(i) Offer to Purchase for Cash All Outstanding Shares of Common Stock ? of TURNING POINT THERAPEUTICS, INC. |
|
| June 17, 2022 |
MUTUAL NON-DISCLOSURE AGREEMENT Exhibit (d)(2) MUTUAL NON-DISCLOSURE AGREEMENT THIS MUTUAL NON-DISCLOSURE AGREEMENT (?Agreement?) is made effective as of March 6, 2022 (the ?Effective Date?), by and between TURNING POINT THERAPEUTICS, INC. |
|
| June 17, 2022 |
MUTUAL NON-DISCLOSURE AGREEMENT Exhibit (e)(3) MUTUAL NON-DISCLOSURE AGREEMENT This Mutual Non-Disclosure Agreement (?Agreement?) is made effective as of March 6, 2022 (the ?Effective Date?), by and between Turning Point Therapeutics, Inc. |
|
| June 3, 2022 |
Employee FAQ, first used on June 3, 2022. EX-99.1 2 d337235dex991.htm EX-99.1 Exhibit 99.1 COMPANY EMPLOYEE FAQS Turning Point Therapeutics—Employee Questions and Answers 1. What was announced regarding the Company and Bristol Myers Squibb? Turning Point Therapeutics (the “Company” or “Turning Point Therapeutics”) and Bristol Myers Squibb (“Bristol Myers Squibb”) have entered into a definitive merger agreement for Bristol Myers Squibb to |
|
| June 3, 2022 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER among: TURNING POINT THERAPEUTICS, INC., a Delaware corporation; BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation; and RHUMBA MERGER SUB INC., a Delaware corporation Dated as of June 2, 2022 TABLE OF CONTENTS Page SECTION 1. THE OFFER 1 1.1 The Offer 1 1.2 Company Actions 3 SECTION 2. MERGER TRANSACTION 4 2.1 Merger of Purchaser into t |
|
| June 3, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2022 TURNING POINT THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38871 46-3826166 (State or other jurisdiction of incorporation) (Comm |
|
| June 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 TURNING POINT THERAPEUTICS, INC. (Name of Subject Company (Issuer)) RHUMBA MERGER SUB INC. (Offeror) A Wholly Owned Subsidiary of BRISTOL-MYERS SQUIBB COMPANY (Offeror) (Name of Filing Persons (identifying status as off |
|
| June 3, 2022 |
Exhibit 99.1 Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company Acquisition Brings Repotrectinib, a Potential Best-in-Class, Next-Generation ROS1/NTRK Inhibitor with Differentiated Duration of Response for Patients with ROS1-positive First-Line Non-Small Cell Lung Cancer; Expected to Launch in 2023 Bristol Myers Squibb to Commence All-Cash Tender Offer |
|
| June 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Turning Point Therapeutics, Inc. (Name of Subject Company) Turning Point Therapeutics, Inc. (Name of Person Filing Statement) Common Stock, $0.0001 par value per share (Title of Class of Securities) 90041T108 (CUS |
|
| June 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Turning Point Therapeutics, Inc. (Name of Subject Company) Turning Point Therapeutics, Inc. (Name of Person Filing Statement) Common Stock, $0.0001 par value per share (Title of Class of Securities) 90041T108 (CUS |
|
| June 3, 2022 |
Exhibit 99.2 Bristol Myers Squibb has agreed to acquire Turning Point Therapeutics, a San-Diego based, clinical-stage biopharmaceutical company that focuses on the discovery and development of innovative, targeted oncology therapeutics. Through this transaction, Bristol Myers Squibb gains repotrectinib, a next generation, potential best-in-class, tyrosine kinase inhibitor (TKI) being developed for |
|
| June 3, 2022 |
Exhibit 99.4 1 1 1 1 1 |
|
| June 3, 2022 |
Letter to Employees, first used on June 3, 2022. Exhibit 99.3 LETTER TO COMPANY EMPLOYEES Dear Turning Point team: Today is a significant day for Turning Point Therapeutics. A few minutes ago, we announced that Bristol Myers Squibb intends to acquire our company for approximately $4.1 billion, or $76.00 per share. Bristol Myers Squibb?s offer is a testament to the value you have all created through your unrelenting dedication and commitment to o |
|
| June 3, 2022 |
Exhibit 99.3 Social Media Content Twitter LinkedIn Additional Information about the Tender Offer and Where to Find it The tender offer described in this communication has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities, nor is it a substitute for the tender offer materials that Bristol-My |
|
| June 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2022 Turning Point Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) (Comm |
|
| June 3, 2022 |
Investor FAQ, first used on June 3, 2022. Exhibit 99.2 INVESTOR FAQS Investor Questions and Answers 1. What role will your executive team have after the merger? Bristol Myers Squibb views our team as a key strength. We will provide more details on these matters as we proceed toward closing. 2. When did discussions between Bristol Myers Squibb and Turning Point Therapeutics begin? How long did this process take? Please refer to our 14d-9, |
|
| June 3, 2022 |
Exhibit 99.1 Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company Acquisition Brings Repotrectinib, a Potential Best-in-Class, Next-Generation ROS1/NTRK Inhibitor with Differentiated Duration of Response for Patients with ROS1-positive First-Line Non-Small Cell Lung Cancer; Expected to Launch in 2023 Bristol Myers Squibb to Commence All-Cash Tender Offer |
|
| May 10, 2022 |
EX-99.1 2 tptx-ex991.htm EX-99.1 Exhibit 99.1 Contact: Adam D. Levy, Ph.D., M.B.A. [email protected] 858-867-6366 TURNING POINT THERAPEUTICS REPORTS FIRST-QUARTER 2022 FINANCIAL RESULTS, PROVIDES OPERATIONAL UPDATES • Granted Third Breakthrough Therapy Designation (BTD) for Repotrectinib for the treatment of patients with ROS1-positive Metastatic NSCLC who have been Previously Treated with One |
|
| May 10, 2022 |
Non-Employee Director Compensation Policy, as amended EX-10.3 3 tptx-ex103.htm EX-10.3 Exhibit 10.3 Turning Point Therapeutics, Inc. Non-Employee Director Compensation Policy Adopted: April 5, 2019 As Amended: March 24, 2022 Each member of the Board of Directors (the “Board”) of Turning Point Therapeutics, Inc. (the “Company”) who is a non-employee director of the Company (each such member, a “Non-Employee Director”) will receive the compensation des |
|
| May 10, 2022 |
EX-99.2 3 tptx-ex992.htm EX-99.2 Next-Generation Precision Oncology Medicines Company Overview May 2022 Exhibit 99.2 Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding our research and clinical development activities, plans and projected timelines, business stra |
|
| May 10, 2022 |
Exhibit 10.2 TURNING POINT THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT for Brian Sun This Executive Employment Agreement (this ?Agreement?), is made and entered into as of 25-March-2022, by and between Brian Sun (?Executive?) and Turning Point Therapeutics, Inc. (the ?Company?). Whereas, the Company desires for Executive to provide services to the Company, and wishes to provide Executive wit |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38871 Turning Point Therapeutics, Inc. |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 Turning Point Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) (Comm |
|
| May 10, 2022 |
Exhibit 10.4 FIRST AMENDMENT TO LEASE This FIRST AMENDMENT TO LEASE ("First Amendment") is made and entered into as of August 31, 2021 (the "Effective Date"), by and between HCP CALLAN ROAD, LLC, a Delaware limited liability company ("Landlord"), and TURNING POINT THERAPEUTICS, INC., a Delaware corporation ("Tenant"). r e c i t a l s : A. Landlord and Tenant are parties to the Lease dated May 20, |
|
| May 5, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 05, 2022 Turning Point Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) (Comm |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 13, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2022 Turning Point Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) (Co |
|
| April 13, 2022 |
EX-99.1 2 tptx-ex991.htm EX-99.1 Repotrectinib Topline TRIDENT-1 Phase 1/2 Data in ROS1+ NSCLC Investor Call and Webcast April 13, 2022 Exhibit 99.1 Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding our research and clinical development activities, plans and pr |
|
| March 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 TURNING POINT THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38871 46-3826166 (State or other jurisdiction of incorporation) |
|
| February 28, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Turning Point Therapeutics, Inc. |
|
| February 28, 2022 |
As filed with the Securities and Exchange Commission on February 28, 2022 As filed with the Securities and Exchange Commission on February 28, 2022 Registration No. |
|
| February 28, 2022 |
Exhibit 99.1 Contact: Adam D. Levy, Ph.D., M.B.A. [email protected] 858-867-6366 TURNING POINT THERAPEUTICS REPORTS FOURTH-QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS, PROVIDES OPERATIONAL UPDATES ? On Track for TRIDENT-1 ROS1+ NSCLC Topline Data Disclosure and Pre-NDA Meeting Anticipated 2Q 2022 ? Eighth Regulatory Designation Granted for Repotrectinib with Breakthrough Therapy Designation i |
|
| February 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 Turning Point Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) |
|
| February 28, 2022 |
Turning Point Therapeutics, Inc. Severance Benefit Plan, as amended (C-Suite) November 11, 2021. Exhibit 10.13 TURNING POINT THERAPEUTICS, INC. SEVERANCE BENEFIT PLAN ? C-SUITE 1. INTRODUCTION. This Turning Point Therapeutics, Inc. Severance Benefit Plan ? C-Suite (the ?Plan?) is established by Turning Point Therapeutics, Inc. (the ?Company?) effective September 18, 2017 (the ?Effective Date?), amended effective September 29, 2018, February 20, 2019 and July 25, 2019 and amended and restated |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38871 Turning Point T |
|
| February 28, 2022 |
Exhibit 10.28 Turning Point Therapeutics, Inc. February 16, 2022 Annette North Executive Vice President and General Counsel Re: Transition Consulting Agreement Dear Annette: This letter sets forth the terms of the transition consulting agreement (the ?Consulting Agreement?) that Turning Point Therapeutics, Inc. (the ?Company?) is offering to you in connection with your resignation from the Company |
|
| February 28, 2022 |
EX-10.27 3 tptx-ex1027.htm EX-10.27 Exhibit 10.27 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE TURNING POINT THERAPEUTICS, INC. HAS DETERMINED THE INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT TURNING POINT THERAPEUTICS, INC. TREATS AS PRIVATE OR CONFIDENTIAL. CLINICAL TRIAL COLLABORATION AGREEMENT This CLINICAL TRIAL COLLABORATION AGREE |
|
| February 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2022 Turning Point Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) |
|
| February 14, 2022 |
TPTX / Turning Point Therapeutics Inc / Cormorant Asset Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Turning Point Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 90041T108 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 10, 2022 |
TPTX / Turning Point Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Turning Point Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 90041T108 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Turning Point Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 90041T108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| January 18, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2022 Turning Point Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) ( |
|
| January 18, 2022 |
EX-99.1 2 tptx-ex991.htm EX-99.1 Exhibit 99.1 Contact: Adam D. Levy, PhD, MBA [email protected] 858-867-6366 TURNING POINT THERAPEUTICS PROVIDES UPDATES AND ANTICIPATED 2022 CLINICAL AND DISCOVERY PIPELINE MILESTONES Strong enrollment within multi-cohort TRIDENT-1 Phase 2 registration enabling study of repotrectinib; completion of targeted 60 patients within EXP-4 ROS1+ TKI-pretreated N |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38871 Turning Point Therapeutics, Inc. |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2021 Turning Point Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) |
|
| November 9, 2021 |
TURNING POINT THERAPEUTICS REPORTS THIRD-QUARTER FINANCIAL RESULTS, PROVIDES OPERATIONAL UPDATES Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Adam Levy [email protected] 858-867-6366 TURNING POINT THERAPEUTICS REPORTS THIRD-QUARTER FINANCIAL RESULTS, PROVIDES OPERATIONAL UPDATES ? Updated Preliminary Clinical Data Presented for Lead Drug Candidate Repotrectinib and Elzovantinib at the AACR-NCI-EORTC Conference ? Multiple FDA Interactions Anticipated in Q4 2021 and 1H 2022 for Repotrectinib |
|
| October 13, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2021 Turning Point Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) ( |
|
| October 8, 2021 |
October 2021 Next-Generation Precision Oncology Medicines Company Overview Exhibit 99. |
|
| October 8, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 08, 2021 Turning Point Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) ( |
|
| October 7, 2021 | ||
| October 7, 2021 |
October 7, 2021 Next-Generation Precision Oncology Medicines AACR-NCI-EORTC Investor Meeting Exhibit 99. |
|
| October 7, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 07, 2021 Turning Point Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) ( |
|
| August 9, 2021 |
Exhibit 10.3 FIRST AMENDMENT THIS FIRST AMENDMENT (the "Amendment") is made and entered into as of June 11, 2021, by and between GATEWAY TORREY HILLS LLC, a Delaware limited liability company, hereafter called "Landlord," and TURNING POINT THERAPEUTICS, INC., a Delaware corporation, hereafter called "Tenant." RECITALS A. Landlord and Tenant are parties to that certain lease dated April 9, 2021 (th |
|
| August 9, 2021 |
Turning Point Therapeutics, Inc. Severance Benefit Plan, as amended (C-Suite) May 4, 2021. EX-10.1 2 tptx-ex10112.htm EX-10.1 Exhibit 10.1 TURNING POINT THERAPEUTICS, INC. SEVERANCE BENEFIT PLAN – C-SUITE 1.INTRODUCTION. This Turning Point Therapeutics, Inc. Severance Benefit Plan – C-Suite (the “Plan”) is established by Turning Point Therapeutics, Inc. (the “Company”) effective September 18, 2017 (the “Effective Date”), amended effective September 29, 2018, February 20, 2019 and July 2 |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38871 Turning Point Therapeutics, Inc. |
|
| August 9, 2021 |
Exhibit 10.2 TURNING POINT THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT for Paolo Tombesi This Executive Employment Agreement (this ?Agreement?), is made and entered into as of 22-June-2021 by and between Paolo Tombesi (?Executive?) and Turning Point Therapeutics, Inc. (the ?Company?). Whereas, the Company desires for Executive to provide services to the Company, and wishes to provide Executi |
|
| August 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) (Co |
|
| August 9, 2021 |
TURNING POINT THERAPEUTICS REPORTS SECOND-QUARTER FINANCIAL RESULTS, PROVIDES OPERATIONAL UPDATES EX-99.1 2 tptx-ex99120.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Jim Mazzola [email protected] 858-342-8272 TURNING POINT THERAPEUTICS REPORTS SECOND-QUARTER FINANCIAL RESULTS, PROVIDES OPERATIONAL UPDATES • Phase 1/2 TRIDENT-1 Enrollment Reaches Approximately 300 Patients, Including More than 50 in the ROS1-Positive TKI-naïve NSCLC Cohort (EXP-1) • TPX-0022 Granted Fast |
|
| June 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2021 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) (Com |
|
| June 7, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2021 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) (Comm |
|
| May 26, 2021 |
EX-10.1 2 tptx-ex1017.htm EX-10.1 Exhibit 10.1 CALLAN RIDGE LEASE This Lease (the "Lease"), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the "Summary"), below, is made by and between HCP CALLAN ROAD, LLC, a Delaware limited liability company ("Landlord"), and TURNING POINT THERAPEUTICS, INC., a Delaware corporation ("Tenant"). SUMMARY OF BASIC LEASE INFORM |
|
| May 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2021 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) (Comm |
|
| May 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini |
|
| May 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2021 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) (Comm |
|
| May 13, 2021 |
Exhibit 10.1 FIRST AMENDMENT TO LEASE AGREEMENT This First Amendment to Lease Agreement (this ?First Amendment?) is made as of May 12, 2021 (?Effective Date?), by and between ARE-SD REGION NO. 44, LLC, a Delaware limited liability company (?Landlord?), and TURNING POINT THERAPEUTICS, INC., a Delaware corporation, as successor-in-interest to REGULUS THERAPEUTICS INC. (?Tenant?). RECITALS A.Landlord |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2021 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) (Comm |
|
| May 5, 2021 |
TURNING POINT THERAPEUTICS REPORTS FIRST-QUARTER FINANCIAL RESULTS, PROVIDES OPERATIONAL UPDATES Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Jim Mazzola [email protected] 858-342-8272 TURNING POINT THERAPEUTICS REPORTS FIRST-QUARTER FINANCIAL RESULTS, PROVIDES OPERATIONAL UPDATES ? FDA Type B Meeting Feedback Supports Discussion of Topline BICR Results for Repotrectinib in TKI-Na?ve ROS1+ NSCLC Patients After 6 Months or Greater Follow-up; FDA Meeting Anticipated in 1Q 2022 ? Inv |
|
| May 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38871 Turning Point Therapeutics, Inc. |
|
| May 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2021 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) (Co |
|
| May 5, 2021 |
Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE TURNING POINT THERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO TURNING POINT THERAPEUTICS, INC. IF PUBLICLY DISCLOSED. Amendment No. 1 to License Agreement This Amendment No. 1 to License Agreement (this ?Amendment |
|
| April 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2021 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) (Com |
|
| April 13, 2021 |
Exhibit 10.1 LEASE BETWEEN GATEWAY TORREY HILLS LLC AND TURNING POINT THERAPEUTICS, INC. LEASE (Short Form) THIS LEASE is made as of April 9, 2021, by and between GATEWAY TORREY HILLS LLC, a Delaware limited liability company, hereafter called ?Landlord,? and TURNING POINT THERAPEUTICS, INC., a Delaware corporation hereafter called ?Tenant.? ARTICLE 1. BASIC LEASE PROVISIONS Each reference in this |
|
| April 7, 2021 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Amendment No. |
|
| April 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Turning Point Therapeutics, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 90041T108 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VI LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) |
|
| April 5, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2021 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) (Com |
|
| April 5, 2021 |
April 5, 2021 Turning Point Therapeutics, Inc. Presentation. April 5, 2021 Initial Preliminary Data from Ongoing SWORD-1 Phase 1/2 Study of TPX-0046 Exhibit 10. |
|
| March 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2021 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) (Co |
|
| March 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2021 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) (Co |
|
| March 1, 2021 |
Exhibit 10.20 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE TURNING POINT THERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO TURNING POINT THERAPEUTICS, INC. IF PUBLICLY DISCLOSED. Execution Version license AGREEMENT This License Agreement (this ?Agreement?) is made as of Jan |
|
| March 1, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2021 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) (Com |
|
| March 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38871 Turning Point T |
|
| March 1, 2021 |
As filed with the Securities and Exchange Commission on March 1, 2021 Registration No. |
|
| March 1, 2021 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Jim Mazzola [email protected] 858-342-8272 TURNING POINT THERAPEUTICS REPORTS FOURTH-QUARTER AND FULL-YEAR FINANCIAL RESULTS, PROVIDES OPERATIONAL UPDATES • Continued Strong Enrollment in TRIDENT-1 Registrational Study, with Phase 1/2 Enrollment in EXP-1 Expected to Reach 50 Patients in 2Q; Type B Meeting with FDA Planned in 2Q • TPX-0131 Ph |
|
| February 17, 2021 |
Exhibit 10.1 ASSIGNMENT AND ASSUMPTION OF LEASE THIS ASSIGNMENT AND ASSUMPTION OF LEASE (this ?Assignment?) is made as of the Execution Date (defined below) by and between REGULUS THERAPEUTICS INC., a Delaware corporation (?Assignor?), and TURNING POINT THERAPEUTICS, INC., a Delaware corporation (?Assignee?). RECITALS A.Pursuant to that certain Lease Agreement dated June 19, 2019 (as amended, the |
|
| February 17, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2021 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Turning Point Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 90041T108 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Turning Point Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 90041T108 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| January 29, 2021 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Jim Mazzola [email protected] 858-342-8272 TURNING POINT THERAPEUTICS REPORTS UPDATED INTERIM DATA FROM REGISTRATIONAL PHASE 2 TRIDENT-1 STUDY OF REPOTRECTINIB IN PATIENTS WITH ROS1-POSITIVE TKI-NAÏVE NON-SMALL CELL LUNG CANCER • Phase 2 Confirmed Objective Response Rate is 93% (95% CI: 68-100); Pooled Phase 1/2 Confirmed Objective Response |
|
| January 29, 2021 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2021 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) ( |
|
| January 11, 2021 |
EX-99.1 Exhibit 99.1 Next-Generation Precision Oncology Medicines Company Overview January 2021Exhibit 99.1 Next-Generation Precision Oncology Medicines Company Overview January 2021 Forward-Looking Statements Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding o |
|
| January 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2021 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) ( |
|
| December 8, 2020 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Jim Mazzola [email protected] 858-342-8272 TURNING POINT THERAPEUTICS GRANTED FDA BREAKTHROUGH THERAPY DESIGNATION FOR REPOTRECTINIB TREATMENT IN PATIENTS WITH ROS1-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT BEEN TREATED WITH A ROS1 TYROSINE KINASE INHIBITOR Updated Data from TRIDENT-1 Study in TKI-Naive Patients with ROS1-P |
|
| December 8, 2020 |
Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2020 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) ( |
|
| December 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2020 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) |
|
| November 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2020 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) |
|
| November 12, 2020 |
TURNING POINT THERAPEUTICS REPORTS THIRD-QUARTER FINANCIAL RESULTS, PROVIDES OPERATIONAL UPDATES Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Jim Mazzola [email protected] 858-342-8272 TURNING POINT THERAPEUTICS REPORTS THIRD-QUARTER FINANCIAL RESULTS, PROVIDES OPERATIONAL UPDATES • Early Interim Data for TRIDENT-1 Phase 2 Study of Repotrectinib and Second Drug Candidate, TPX-0022, Recently Presented • Phase 2 TRIDENT-1 Registrational Study Full Site Activation and Timeline Update |
|
| November 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38871 Turning Point Therapeutics, Inc. |
|
| November 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 2) * INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 TURNING POINT THERAPETUICS, INC. (Name of Issuer) Common Stock, Par Value $0.0001 (Title of Class of Securities) 90041T 10 8 |
|
| October 27, 2020 |
Turning Point Therapeutics Announces Pricing of $400 Million Public Offering of Common Stock EX-99.2 Exhibit 99.2 Turning Point Therapeutics Announces Pricing of $400 Million Public Offering of Common Stock SAN DIEGO, Oct. 26, 2020 – Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the pricing of its previously announced underwritten public offering of 4,597,702 shares |
|
| October 27, 2020 |
Financial Statements and Exhibits, Other Events - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2020 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporatio |
|
| October 27, 2020 |
Turning Point Therapeutics Announces Commencement of Public Offering of Common Stock EX-99.1 Exhibit 99.1 Turning Point Therapeutics Announces Commencement of Public Offering of Common Stock SAN DIEGO, Oct. 26, 2020 – Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to |
|
| October 27, 2020 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-238300 CALCULATION OF REGISTRATION FEE TITLE OF EACH CLASS OF SECURITIES TO BE REGISTERED AMOUNT TO BE REGISTERED PROPOSED MAXIMUM OFFERING PRICE PER SHARE PROPOSED MAXIMUM AGGREGATE OFFERING PRICE AMOUNT OF REGISTRATION FEE(2) Common Stock, $0.0001 par value per share 5,287,357(1) $87.00 $460,000,059.00 $50,186.01 (1) I |
|
| October 27, 2020 |
EX-1.1 Exhibit 1.1 EXECUTION VERSION Turning Point Therapeutics, Inc. Common Stock Underwriting Agreement October 26, 2020 Goldman Sachs & Co. LLC SVB Leerink LLC As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 c/o SVB Leerink LLC 255 California Street, 12th Floor San Francisco, C |
|
| October 26, 2020 |
EX-99.2 Exhibit 99.2 FOR IMMEDIATE RELEASE Contact: Jim Mazzola [email protected] 858-342-8272 TURNING POINT THERAPEUTICS PRESENTS INITIAL CLINICAL DATA FROM PHASE 1 SHIELD-1 STUDY OF NOVEL MET/SRC/CSF1R INHIBITOR TPX-0022 AT 2020 EORTC-NCI-AACR SYMPOSIUM • Preliminary Clinical Activity and Safety Profile Support Advancing to Dose Expansion in Multiple Tumor Types • Recommended Phase |
|
| October 26, 2020 |
Financial Statements and Exhibits, Other Events - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2020 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporatio |
|
| October 26, 2020 |
Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2020 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorpo |
|
| October 26, 2020 |
SUBJECT TO COMPLETION, DATED OCTOBER 26, 2020 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-238300 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and we are not soliciting offers to buy these securities, in any state or other jurisdiction where the offe |
|
| October 26, 2020 |
EX-99.1 October 2020 Next-Generation Precision Oncology Medicines Company Overview Exhibit 99.1 Forward-Looking Statements Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding our research and clinical development activities, plans and projected timelines, busines |
|
| August 19, 2020 |
EX-99.1 TRIDENT-1 Phase 2 Study of Repotrectinib: Early Interim Data Update August 19, 2020 Exhibit 99.1 Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding our research and clinical development activities, plans and projected timelines, business strategy and pla |
|
| August 19, 2020 |
EX-99.2 Exhibit 99.2 FOR IMMEDIATE RELEASE Contact: Jim Mazzola [email protected] 858-342-8272 TURNING POINT THERAPEUTICS REPORTS EARLY INTERIM DATA FROM REGISTRATIONAL PHASE 2 TRIDENT-1 STUDY OF REPOTRECTINIB, PROVIDES REGULATORY UPDATE • ROS1+ TKI-Naïve Non-Small Cell Lung Cancer Confirmed Objective Response Rate is 86 Percent • ROS1+ TKI-Pretreated Non-Small Cell Lung Cancer with O |
|
| August 19, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2020 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorpor |
|
| August 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2020 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) (C |
|
| August 10, 2020 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-238300 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Proposed Maximum Aggregate Offering Price Amount of Registration Fee(1) Common Stock, $0.0001 par value per share $250,000,000 $32,450(1) (1) Calculated in accordance with Rule 457(o) under the Securities Act of 1933, as amended (th |
|
| August 10, 2020 |
EX-1.1 Exhibit 1.1 Execution Version OPEN MARKET SALE AGREEMENT SM August 10, 2020 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Turning Point Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent |
|
| August 10, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2020 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorpor |
|
| August 10, 2020 |
Exhibit 10.4 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE TURNING POINT THERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO TURNING POINT THERAPEUTICS, INC. IF PUBLICLY DISCLOSED. Execution Version license AGREEMENT This License Agreement (this “Agreement”) is made as of July |
|
| August 10, 2020 |
TURNING POINT THERAPEUTICS REPORTS SECOND-QUARTER FINANCIAL RESULTS, PROVIDES OPERATIONAL UPDATES Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Jim Mazzola [email protected] 858-342-8272 TURNING POINT THERAPEUTICS REPORTS SECOND-QUARTER FINANCIAL RESULTS, PROVIDES OPERATIONAL UPDATES • Early Interim Data from Registrational Phase 2 TRIDENT-1 Study of Lead Drug Candidate Repotrectinib Anticipated in Third Quarter • Four Clinical Studies of Three Drug Candidates Ongoing; Early Interim |
|
| August 10, 2020 |
F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38871 Turning Point Therapeutics, Inc. |
|
| August 10, 2020 |
Exhibit 10.3 Turning Point Therapeutics, Inc. 2019 Equity Incentive Plan Restricted Stock Unit Grant Notice Turning Point Therapeutics, Inc. (the “Company”), pursuant to its 2019 Equity Incentive Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (the “Award”). The Award is |
|
| August 10, 2020 |
Exhibit 10.2 TURNING POINT THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT for ANDREW PARTRIDGE This Executive Employment Agreement (this “Agreement”), is made and entered into as of June 26, 2020, by and between Andrew Partridge (“Executive”) and Turning Point Therapeutics, Inc. (the “Company”). Whereas, the Company desires for Executive to provide services to the Company, and wishes to provide |
|
| August 10, 2020 |
Exhibit 10.1 Turning Point Therapeutics, Inc. Non-Employee Director Compensation Policy Adopted: April 5, 2019 Amended: January 6, 2020 Amended: June 15, 2020 Each member of the Board of Directors (the “Board”) of Turning Point Therapeutics, Inc. (the “Company”) who is a non-employee director of the Company (each such member, a “Non-Employee Director”) will receive the compensation described in th |
|
| July 7, 2020 |
Entry into a Material Definitive Agreement 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2020 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) ( |
|
| June 17, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2020 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) (Com |
|
| May 26, 2020 |
WAIVER OF REGISTRATION RIGHTS AND NOTICE GLAXOSMITHKLINE PLC SC 13D/A Exhibit 4 WAIVER OF REGISTRATION RIGHTS AND NOTICE This Waiver of Registration Rights and Notice (this “Waiver”), dated as of May 15, 2020, is entered into by and among Turning Point Therapeutics, Inc. |
|
| May 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1) * INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 TURNING POINT THERAPETUICS, INC. (Name of Issuer) Common Stock, Par Value $0.0001 (Title of Class of Securities) 90041T 10 8 |
|
| May 26, 2020 |
Turning Point Therapeutics, Inc. Lock-Up Agreement GLAXOSMITHKLINE PLC SC 13D/A Exhibit 3 Turning Point Therapeutics, Inc. Lock-Up Agreement May , 2020 Goldman Sachs & Co. LLC SVB Leerink LLC c/o Goldman Sachs & Co. LLC 200 West Street New York, NY 10282-2198 c/o SVB Leerink LLC 255 California Street, 12th Floor San Francisco, CA 94111 Re: Turning Point Therapeutics, Inc. - Lock-Up Agreement Ladies and Gentlemen: The undersigned understands that y |
|
| May 22, 2020 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Amendment No. |
|
| May 22, 2020 |
TPTX / Turning Point Therapeutics, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Turning Point Therapeutics, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 90041T108 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VI LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) |
|
| May 19, 2020 |
EX-1.1 Exhibit 1.1 Turning Point Therapeutics, Inc. Common Stock Underwriting Agreement May 18, 2020 Goldman Sachs & Co. LLC SVB Leerink LLC As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 c/o SVB Leerink LLC 255 California Street, 12th Floor San Francisco, California 94111 Ladies |
|
| May 19, 2020 |
Turning Point Therapeutics Announces Pricing of $325 Million Public Offering of Common Stock EX-99.2 Exhibit 99.2 Turning Point Therapeutics Announces Pricing of $325 Million Public Offering of Common Stock May 18, 2020 SAN DIEGO, May 18, 2020 (GLOBE NEWSWIRE) – Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the pricing of its previously announced underwritten public |
|
| May 19, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2020 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) ( |
|
| May 19, 2020 |
Turning Point Therapeutics Announces Commencement of Public Offering of Common Stock EX-99.1 Exhibit 99.1 Turning Point Therapeutics Announces Commencement of Public Offering of Common Stock May 18, 2020 SAN DIEGO, May 18, 2020 (GLOBE NEWSWIRE) – Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that it has commenced an underwritten public offering, subject to ma |
|
| May 19, 2020 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-238300 CALCULATION OF REGISTRATION FEE TITLE OF EACH CLASS OF SECURITIES TO BE REGISTERED AMOUNT TO BE REGISTERED PROPOSED MAXIMUM OFFERING PRICE PER SHARE PROPOSED MAXIMUM AGGREGATE OFFERING PRICE AMOUNT OF REGISTRATION FEE(2) Common Stock, $0.0001 par value per share 6,229,167(1) $60.00 $373,750,020.00 $48,512.76 (1) I |
|
| May 18, 2020 |
EX-99.1 Exhibit 99.1 BUSINESS Overview We are a clinical-stage biopharmaceutical company designing and developing novel small molecule, targeted oncology therapies to address key limitations of existing therapies and improve the lives of patients. Our internally developed and wholly owned pipeline of next-generation tyrosine kinase inhibitors (TKIs) targets numerous genetic drivers of cancer in bo |
|
| May 18, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2020 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) ( |
|
| May 18, 2020 |
SUBJECT TO COMPLETION, DATED MAY 18, 2020 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-238300 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and we are not soliciting offers to buy these securities, in any state or other jurisdiction where the offe |
|
| May 15, 2020 |
Form of Common Stock Warrant Agreement and Warrant Certificate. EX-4.9 Exhibit 4.9 TURNING POINT THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF TURNING POINT THERAPEUTICS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between Turning Point Therapeutics, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking asso |
|
| May 15, 2020 |
EX-4.6 Exhibit 4.6 TURNING POINT THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s C |
|
| May 15, 2020 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. EX-4.11 Exhibit 4.11 TURNING POINT THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF TURNING POINT THERAPEUTICS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [●], between Turning Point Therapeutics, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national b |
|
| May 15, 2020 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. EX-4.10 Exhibit 4.10 TURNING POINT THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF TURNING POINT THERAPEUTICS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between Turning Point Therapeutics, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national b |
|
| May 15, 2020 |
S-3ASR Table of Contents As filed with the Securities and Exchange Commission on May 15, 2020 Registration No. |
|
| May 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38871 Turning Point Therapeutics, Inc. |
|
| May 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2020 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) (Comm |
|
| May 12, 2020 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Jim Mazzola [email protected] 858-342-8272 TURNING POINT THERAPEUTICS REPORTS FIRST-QUARTER FINANCIAL RESULTS, PROVIDES UPDATE ON OPERATIONS AND COVID-19 RESPONSE • Repotrectinib Granted Fast Track Designation in ROS1-Positive Advanced Non-Small Cell Lung Cancer Patients Not Previously Treated with a ROS1 Tyrosine Kinase Inhibitor • First Qu |
|
| April 29, 2020 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 29, 2020 |
DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| March 18, 2020 |
Exhibit 4.3 DESCRIPTION OF COMMON STOCK The following summary description of the common stock of Turning Point Therapeutics, Inc. (we, our or us) is based on the provisions of our amended and restated certificate of incorporation, as well as our amended and restated bylaws, and the applicable provisions of the Delaware General Corporation Law. This information is qualified entirely by reference to |
|
| March 18, 2020 |
Exhibit 10.14 TURNING POINT THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT for SIEGFRIED REICH, PH.D. This Executive Employment Agreement (this “Agreement”), is made and entered into as of February 15, 2020, by and between Siegfried Reich, Ph.D., (“Executive”) and Turning Point Therapeutics, Inc. (the “Company”). WHEREAS, the Company desires for Executive to provide services to the Company, and |
|
| March 18, 2020 |
March 18, 2020 (File No. 333-237250) S-8 As filed with the Securities and Exchange Commission on March 17, 2020 Registration No. |
|
| March 18, 2020 |
Non-Employee Director Compensation Policy as amended January 06, 2020. Exhibit 10.12 Turning Point Therapeutics, Inc. Non-Employee Director Compensation Policy Adopted: April 5, 2019 Amended: January 6, 2020 Each member of the Board of Directors (the “Board”) of Turning Point Therapeutics, Inc. (the “Company”) who is a non-employee director of the Company (each such member, a “Non-Employee Director”) will receive the compensation described in this Non-Employee Direct |
|
| March 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38871 Turning Point T |
|
| March 18, 2020 |
Turning Point Therapeutics, Inc. Severance Benefit Plan, as amended (C-Suite) February 15, 2020. Exhibit 10.15 Turning Point Therapeutics, Inc. Severance Benefit Plan – C-Suite 1.Introduction. This Turning Point Therapeutics, Inc. Severance Benefit Plan – C-Suite (the “Plan”) is established by Turning Point Therapeutics, Inc. (the “Company”) effective September 18, 2017 (the “Effective Date”), amended effective September 29, 2018, February 20, 2019 and July 25, 2019 and amended and restated F |
|
| March 16, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2020 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) (Co |
|
| March 16, 2020 |
TURNING POINT THERAPEUTICS REPORTS FOURTH-QUARTER, FULL- YEAR 2019 FINANCIAL AND OPERATIONAL RESULTS Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Jim Mazzola [email protected] 858-342-8272 TURNING POINT THERAPEUTICS REPORTS FOURTH-QUARTER, FULL- YEAR 2019 FINANCIAL AND OPERATIONAL RESULTS • Registrational Phase 2 TRIDENT-1 Study Continues Site Activation and Patient Enrollment • Preclinical Data Highlighting Repotrectinib Combinations and Additional Data for TPX-0131 to be Presented i |
|
| February 14, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1)* Turning Point Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 90041T108 (CUSIP Number) December 31, 2019 |
|
| February 14, 2020 |
TPTX / Turning Point Therapeutics, Inc. / Cormorant Asset Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Turning Point Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 90041T108 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| February 11, 2020 |
TPTX / Turning Point Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Turning Point Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 90041T108 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d |
|
| February 5, 2020 |
TPTX / Turning Point Therapeutics, Inc. / Cui Jingrong Jean - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 Turning Point Therapeutics, Inc. |
|
| January 23, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2020 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporatio |
|
| January 13, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2020 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporatio |
|
| January 13, 2020 |
EX-99.1 38th Annual J.P. Morgan Healthcare Conference Next-Generation Precision Oncology Medicines Athena Countouriotis, M.D., President and CEO January 15, 2020 Exhibit 99.1 Disclaimer Forward-Looking Statements Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regardin |
|
| January 13, 2020 |
TURNING POINT THERAPEUTICS ANNOUNCES PROGRAM UPDATES AND MILESTONES FOR 2020 EX-99.2 Exhibit 99.2 FOR IMMEDIATE RELEASE Contact: Jim Mazzola [email protected] 858-342-8272 TURNING POINT THERAPEUTICS ANNOUNCES PROGRAM UPDATES AND MILESTONES FOR 2020 • Repotrectinib Granted Fast Track Designation in Previously Treated ROS1-Positive Advanced Non-Small Cell Lung Cancer Patient Subset; Registrational Phase 2 Study Continues Site Activation and Patient Enrollment • |
|
| January 9, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2020 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation |
|
| January 9, 2020 |
EX-10.1 Exhibit 10.1 TURNING POINT THERAPEUTICS, INC. January 9, 2020 Jingrong Jean Cui, Ph.D. c/o Turning Point Therapeutics, Inc. Re: Transition Separation and Consulting Agreement Dear Jean: This letter sets forth the terms of the transition separation and consulting agreement (the “Agreement”) that Turning Point Therapeutics, Inc. (the “Company”) is offering to you to aid in your employment tr |
|
| November 4, 2019 |
TPTX / Turning Point Therapeutics, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38871 Turning Point Therapeutics, Inc. |
|
| November 4, 2019 |
Exhibit 10.3 TURNING POINT THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT for MOHAMMAD HIRMAND, M.D. This Executive Employment Agreement (this “Agreement”), is made and entered into as of October 30, 2019, by and between Mohammad Hirmand, M.D., (“Executive”) and Turning Point Therapeutics, Inc. (the “Company”). Whereas, the Company desires for Executive to provide services to the Company, and w |
|
| November 4, 2019 |
TURNING POINT THERAPEUTICS REPORTS THIRD QUARTER 2019 FINANCIAL AND OPERATIONAL RESULTS Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Jim Mazzola [email protected] 858-342-8272 TURNING POINT THERAPEUTICS REPORTS THIRD QUARTER 2019 FINANCIAL AND OPERATIONAL RESULTS • Registrational Phase 2 Study of Repotrectinib Ongoing • Phase 1/2 Clinical Studies of RET/SRC Inhibitor TPX-0046 and Repotrectinib in Pediatric Patients On Track to Initiate in 2019 • Mohammad Hirmand, M.D. Nam |
|
| November 4, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2019 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) ( |
|
| September 6, 2019 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2019 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporati |
|
| September 6, 2019 |
Turning Point Therapeutics Announces Pricing of Public Offering of Common Stock EX-99.1 Exhibit 99.1 Turning Point Therapeutics Announces Pricing of Public Offering of Common Stock SAN DIEGO, September 5, 2019 (GLOBE NEWSWIRE) – Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced the pricing of its public offering of 4,500,000 shares of common stock at a price to the public of $4 |
|
| September 6, 2019 |
424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-233602 PROSPECTUS 4,500,000 Shares Common Stock We are selling 4,500,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol “TPTX”. On September 5, 2019, the last reported sale price of our common stock as reported on the Nasdaq Global Select Market was $46.96 per s |
|
| September 3, 2019 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2019 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporati |
|
| September 3, 2019 |
EX-99.1 Exhibit 99.1 BUSINESS Overview We are a clinical-stage biopharmaceutical company designing and developing novel small molecule, targeted oncology therapies to address key limitations of existing therapies and improve the lives of patients. Our internally developed and wholly owned pipeline of next-generation tyrosine kinase inhibitors (TKIs) targets numerous genetic drivers of cancer in bo |
|
| September 3, 2019 |
Form of Underwriting Agreement. EX-1.1 Exhibit 1.1 Turning Point Therapeutics, Inc. Common Stock Underwriting Agreement [ ], 2019 Goldman Sachs & Co. LLC SVB Leerink LLC, As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 c/o SVB Leerink LLC 255 California Street, 12th Floor San Francisco, California 94111 Ladies a |
|
| September 3, 2019 |
TPTX / Turning Point Therapeutics, Inc. S-1 - Registration Statement - S-1 S-1 Table of Contents As filed with the U.S. Securities and Exchange Commission on September 3, 2019. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Turning Point Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 46-3826166 (State or Other Jurisdicti |
|
| September 3, 2019 |
TPTX / Turning Point Therapeutics, Inc. CORRESP - - CORRESP TURNING POINT THERAPEUTICS, INC. 10628 Science Center Drive, Ste. 200 San Diego, California 92121 September 3, 2019 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tonya K. Aldave Re: Turning Point Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-233602) Request for Acceleration of Effectiv |
|
| September 3, 2019 |
TPTX / Turning Point Therapeutics, Inc. CORRESP - - CORRESP Goldman Sachs & Co. LLC 200 West Street, New York, New York 10282-2198 SVB Leerink LLC 255 California Street, 12 Floor San Francisco, California 94111 September 3, 2019 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Turning Point Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-233602) Reque |
|
| August 19, 2019 |
TPTX / Turning Point Therapeutics, Inc. DRS - - DRS Table of Contents Confidential Treatment Requested by Turning Point Therapeutics, Inc. |
|
| August 6, 2019 |
TURNING POINT THERAPEUTICS REPORTS SECOND QUARTER 2019 FINANCIAL AND OPERATIONAL RESULTS Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Jim Mazzola [email protected] 858-342-8272 TURNING POINT THERAPEUTICS REPORTS SECOND QUARTER 2019 FINANCIAL AND OPERATIONAL RESULTS • FDA Accepts Repotrectinib Recommended Phase 2 Dose Regimen for Registrational TRIDENT-1 Study • Two Abstracts Selected for Presentation at the European Society for Medical Oncology (ESMO) Annual Congress Highl |
|
| August 6, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2019 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) (Co |
|
| August 6, 2019 |
TPTX / Turning Point Therapeutics, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38871 Turning Point Therapeutics, Inc. |
|
| July 29, 2019 |
EX-10.1 Exhibit 10.1 TURNING POINT THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT for YI LARSON This Executive Employment Agreement (this “Agreement”), is made and entered into as of July 25, 2019, by and between Yi Larson (“Executive”) and Turning Point Therapeutics, Inc. (the “Company”). WHEREAS, the Company desires for Executive to provide services to the Company, and wishes to provide Execu |
|
| July 29, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2019 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) |
|
| July 29, 2019 |
EX-10.2 Exhibit 10.2 TURNING POINT THERAPEUTICS, INC. SEVERANCE BENEFIT PLAN – C-SUITE 1. INTRODUCTION. This Turning Point Therapeutics, Inc. Severance Benefit Plan – C-Suite (the “Plan”) is established by Turning Point Therapeutics, Inc. (the “Company”) effective September 18, 2017 (the “Effective Date”), amended effective September 29, 2018, February 20, 2019 and amended and restated July 25, 20 |
|
| July 25, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2019 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) |
|
| June 21, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2019 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) (Com |
|
| June 21, 2019 |
Exhibit 10.2 THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (this “Third Amendment”) is made as of June 19, 2019, by and between ARE-SD REGION NO. 44, LLC, a Delaware limited liability company (“Landlord”), and TURNING POINT THERAPEUTICS, INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are now parties to certain Lease dated as of January 19, 2016, as amended by tha |
|
| June 21, 2019 |
Exhibit 10.1 LEASE AGREEMENT THIS LEASE AGREEMENT (this “Lease”) is made this 19th day of June, 2019, between ARE-SD REGION NO. 44, LLC, a Delaware limited liability company (“Landlord”), and TURNING POINT THERAPEUTICS, INC., a Delaware corporation (“Tenant”). Building: 10628 Science Center Drive, San Diego, California Premises: That certain portion of the Building known as (i) Suite 100, containi |
|
| May 31, 2019 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Jim Mazzola [email protected] 858-342-8272 TURNING POINT THERAPEUTICS ANNOUNCES UPDATED INTERIM CLINICAL DATA OF REPOTRECTINIB IN ADVANCED ROS1+ NON-SMALL CELL LUNG CANCER • In TKI-naïve ROS1+ Patients, Overall Response Rate by Blinded Review is 82 Percent, and 83 Percent at Likely Recommended Phase 2 Dose of 160 mg QD or Above; Median Durat |
|
| May 31, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2019 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) (Comm |
|
| May 31, 2019 |
TPTX / Turning Point Therapeutics, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38871 Turning Point Therapeutics, Inc. |
|
| May 14, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2019 TURNING POINT THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38871 46-3826166 (State or Other Jurisdiction of Incorporation) ( |
|
| May 14, 2019 |
TURNING POINT THERAPEUTICS NAMES BIOTECH VETERAN PATRICK MACHADO, J.D. TO ITS BOARD OF DIRECTORS EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Jim Mazzola [email protected] 858-342-8272 TURNING POINT THERAPEUTICS NAMES BIOTECH VETERAN PATRICK MACHADO, J.D. TO ITS BOARD OF DIRECTORS SAN DIEGO, May 14, 2019 – Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced the appointment of |
|
| May 10, 2019 |
S-8 As filed with the Securities and Exchange Commission on May 10, 2019 Registration No. |
|
| May 2, 2019 |
TPTX / Turning Point Therapeutics, Inc. / Foresite Capital Fund Iv, L.p. - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. )* Turning Point Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 90041T108 (CUSIP Number) April 22, 2019 (Dat |
|
| April 26, 2019 |
TPTX / Turning Point Therapeutics, Inc. / GLAXOSMITHKLINE PLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 TURNING POINT THERAPEUTICS, INC. (Name of Issuer) Common Stock, Par Value $0.0001 (Title of Class of Securities) 90041T 10 8 (CUSIP Number) Victo |
|
| April 25, 2019 |
TPTX / Turning Point Therapeutics, Inc. / Cormorant Asset Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Turning Point Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 90041T108 (CUSIP Number) April 22, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| April 25, 2019 |
Exhibit 1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of April 25, 2019, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare Fund I, LP, Cormorant Private Healthcare GP, LLC, Cormorant Private Healthcare Fund II, LP, Cormorant Private Healthcare GP II, LLC, Cormorant Asset Management, LP and Bihua Chen (collectively, the “Filers”). |
|
| April 24, 2019 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated April 24, 2019, with respect to the ordinary shares of Turning Point Therapeutics, Inc. |
|
| April 24, 2019 |
TPTX / Turning Point Therapeutics, Inc. / ORBIMED ADVISORS LLC - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Turning Point Therapeutics, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 90041T108 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VI LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, Ad |
|
| April 22, 2019 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: Jim Mazzola [email protected] 858-342-8272 TURNING POINT THERAPEUTICS ANNOUNCES CLOSING OF INITIAL PUBLIC OFFERING AND FULL EXERCISE OF UNDERWRITERS’ OPTION TO PURCHASE ADDITIONAL SHARES SAN DIEGO, April 22, 2019 – Turning Point Therapeutics, Inc. (Nasdaq:TPTX), a clinical-stage precision oncology company designing and developing nov |
|
| April 22, 2019 |
EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF TURNING POINT THERAPEUTICS, INC. ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Lewes, County of Sussex. Section 2. Other Offices. The corporation shall also have and maintain an office or principal place of business at such place as may be fixed by the corpo |
|
| April 22, 2019 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TURNING POINT THERAPEUTICS, INC. Athena Maria Countouriotis, M.D., hereby certifies that: ONE: She is the duly elected and acting President and Chief Executive Officer of Turning Point Therapeutics, Inc., a Delaware corporation. TWO: The original name of the corporation is TP Therapeutics, Inc. and the original date of filing |
|
| April 22, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2019 Turning Point Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38871 46-3826166 (state or other jurisdiction of incorporation) |
|
| April 18, 2019 |
424B4 Table of Contents File Pursuant to Rule 424(b)(4) Registration Nos. 333-230428 and 333-230911 PROSPECTUS 9,250,000 Shares Common Stock This is the initial public offering of 9,250,000 shares of common stock of Turning Point Therapeutics, Inc. Prior to this offering, there has been no public market for our common stock. The initial public offering price is $18.00 per share. Our common stock h |
|
| April 17, 2019 |
FWP Issuer Free Writing Prospectus dated April 16, 2019 Filed Pursuant to Rule 433 of the Securities Act of 1933 Relating to Preliminary Prospectus dated April 16, 2019 Registration Statement No. |
|
| April 16, 2019 |
TPTX / Turning Point Therapeutics, Inc. S-1/A NO. 3 S-1/A No. 3 Table of Contents As filed with the U.S. Securities and Exchange Commission on April 16, 2019. Registration No. 333-230428 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Turning Point Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 46-3826 |
|
| April 16, 2019 |
S-1MEF As filed with the Securities and Exchange Commission on April 16, 2019. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Turning Point Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 46-3826166 (State or other jurisdiction of incorporation or |
|
| April 15, 2019 |
8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Turning Point Therapeutics, Inc. |
|
| April 15, 2019 |
TPTX / Turning Point Therapeutics, Inc. CORRESP CORRESP TURNING POINT THERAPEUTICS, INC. 10628 Science Center Drive, Ste. 225 San Diego, California 92121 April 15, 2019 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Justin Dobbie Don Field Tonya K. Aldave Re: Turning Point Therapeutics, Inc. Registration Statement on Form S-1, as amended (File No. 333-230428) Req |
|
| April 15, 2019 |
TPTX / Turning Point Therapeutics, Inc. CORRESP CORRESP Goldman Sachs & Co. LLC 200 West Street, New York, New York 10282-2198 SVB Leerink LLC 255 California Street, 12th Floor San Francisco, California 94111 April 15, 2019 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Turning Point Therapeutics, Inc. Registration Statement on Form S-1, as amended (File No. 333-23 |
|
| April 12, 2019 |
As filed with the U.S. Securities and Exchange Commission on April 12, 2019. Table of Contents As filed with the U.S. Securities and Exchange Commission on April 12, 2019. Registration No. 333-230428 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Turning Point Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 46-3826166 (State o |
